Predicine
Predicine is a global molecular insights company, committed to advancing precision medicine in oncology, and infectious disease diagnostics. Predicine is developing proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technologies to enable minimally invasive molecular diagnosis for early cancer detection, treatment selection, therapy response, MRD monitoring and disease progression.
Precision for Medicine
Precision for Medicine is an industry-leading global precision medicine clinical research organization and a leader in complex clinical development. Our clients benefit from advanced technologies and new approaches that compress timelines, gain efficiencies, and increase the probability of approval. Under one global roof, Precision has integrated sophisticated biomarker capabilities and laboratory expertise, worldwide CRO services, technical manufacturing solutions, and more. With 6 specialty labs and 3,500+ professionals worldwide, we help clients accelerate life-changing treatments and propel medicine forward.
Precision Epigenomics
Precision Epigenomics® Inc. is an innovative molecular diagnostics company focused on revolutionizing early cancer detection through liquid biopsy testing. By analyzing the epigenome – the complex system that controls expression of DNA – we can detect hidden cancers through screening, study patients for the presence of any residual cancer following treatment, and follow survivors for surveillance of cancer recurrence. With a commitment to advancing the field of molecular diagnostics, we aim to create significant value in the rapidly growing oncology diagnostics market, and, above all, to improve the outcomes and lives of many patients affected by cancer. The Problem In 2025, more than 2 million new cancer cases are projected to be diagnosed in the United States–many of them at late stages. Screening protocols for some cancers such as breast or lung cancer have made some progress, but perform poorly due to patients now knowing which test to take and when, the financial and time commitment, discomfort, and low accuracy. Globally more than 20 Million new cases and 10 Million dying each year from cancer, this is unacceptable. The Solution Liquid biopsies present a minimally invasive sampling process (blood or other fluid collection from a patient) that have been gaining momentum as a validated diagnostic tool. Precision Epigenomics has developed and launched a novel blood-based testing protocol, EPISEEK, which identifies a unique set of DNA biomarkers that consistently change in human cancers, but remain stable in normal tissues. Our proprietary bioinformatics analysis can detect abnormal methylation signals present in more than 60 types of cancer. EPISEEK has demonstrated better accuracy compared to other liquid biopsy tests for detecting brain, pancreas, and lung cancer types, among others. Our qPCR platform is a lower cost structure than commonly used sequencing platforms, has faster turnaround times, is globally scalable, and can be applied to pleural fluid, cerebral spinal fluid, and other biospecimens as our product portfolio expands. With these technology advantages, with our CLIA lab-validated and available EPISEEK™ test, and with a focused pipeline of first-to-market tests for specific medical uses, Precision Epigenomics is positioned to save lives and flourish in the rapidly growing liquid biopsy market. Market Opportunity The U.S. market for early cancer detection is a fast-emerging, multi-billion-dollar opportunity, driven by demand for non-invasive sample collection, favorable regulatory trends, and payer support. As multi-cancer early detection (MCED) technologies gain traction screening asymptomatic and high-risk patients, the market is poised for rapid expansion and long-term disruption of traditional cancer diagnostics. Estimated market size for MCED screening: $74+B; CNS-Glioma detection: $1.1B; Malignant Pleural Effusion: $2.1B; Melanoma: $.5B; Head & Neck: $.5B. Commercialization Strategy With EPISEEK™ now optimized, validated, and orderable from our Tucson-based clinical laboratory, we are implementing our commercialization plans immediately for growth. We are focused on key partnerships that will drive volume: commercial labs, imaging collaborators, large concierge medicine practices, employee benefit programs, and high-risk patient groups. With sales and marketing staff now on board, we have launched targeted programs to build awareness, communicate our differentiation, and grow quickly. In the next two years, we will launch two new products that will be first to market in each category, offering physicians a less-invasive test to improve patient care for pulmonary and glioma patients. These products will be commercialized as broadly reimbursed tests, championed by key opinion leaders, supported by peer-reviewed publications and ongoing clinical data generation, and sold to practicing physicians through a highly specialized product sales force.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Precede Biosciences
Precede Biosciences is a precision diagnostics and data company redefining what can be learned from a simple blood draw. By unlocking genome-wide transcriptional biology through a novel, comprehensive epigenomics approach, the company enables researchers and clinicians to better understand disease biology in real time. By partnering with developers of new medicines and advancing its own diagnostic tests, Precede Bio is working toward a future in which drug development efforts succeed more frequently and patients can receive minimally invasive diagnostics and treatments aligned to the biology of their disease.
POWERSITE
Powersite is a world leading provider of comprehensive solutions of key components for advanced X-ray imaging system for both medical and industrial. We offer solutions and services meeting our customers’ needs and aid to streamline their business by providing reliable, quality and advanced components for imaging providers, and by providing our know-how of integrated systems with professional support from product development to after-sales service. Our broad range of product portfolio perfectly applies to DR, CT scanner, dental screening, border security, cargo inspection, NDT (non-destructive testing), EOD (explosive ordnance disposal) and food safety. We’re looking to join your business growth journey enhancing healthcare as well as security.
POSKOM Co Ltd
Polymatech
Polymatech Electronics proudly stands as India’s first semiconductor chip manufacturer. With a relentless focus on innovation, precision, and quality, Our mission is to empower industries and societies with cutting-edge semiconductor solutions. Come to our booth to see our LEDs, including UV for industrial curing and our Veinfinder. | Polymatech Electronics proudly stands as India’s first semiconductor chip manufacturer. With a relentless focus on innovation, precision, and quality, Our mission is to empower industries and societies with cutting-edge semiconductor solutions. Come to our booth to see our FDA registered Vein Finder and Healthcare LEDs.
Pluto Bio
Pluto Bio is the translational alignment platform for drug discovery teams working with complex multi-omic evidence. Pluto helps scientists analyse, interpret, and connect biological evidence across targets, models, mechanisms, and disease context. Instead of rebuilding the scientific story from scattered tools, slides, and reviews, teams can see what is supported, missing, or conflicted directly inside the work. Powered by the Translational Alignment Framework™, Pluto makes program-level biological truth visible so teams can move from fragmented analysis to clearer translational confidence. Visit Pluto Bio at Booth 4513 at AACR 2026.
Planmed Inc
he Finnish Planmed Oy dedicates its effort to the development, manufacturing and marketing of advanced imaging equipment and accessories that provide a unique combination of image quality and ease of use for medical imaging professionals. The company offers products for mammography and orthopedic imaging that are well-known for imaging performance, user-friendliness and good ergonomics. Since 1987, Planmed systems have provided tools for healthcare professionals in over 80 countries worldwide. The company is part of Finnish Planmeca Group, a well-known company in medical and dental field. | Planmed Oy develops, manufactures and markets advanced imaging equipment and accessories for mammography and orthopedic imaging. Planmed’s extensive mammography product range covers digital and analog mammography units and digital breast tomosynthesis (DBT) systems, stereotactic biopsy devices, and breast positioning systems for an early detection of breast cancer. Within orthopedic 3D imaging Planmed offers low dose Cone Beam CT imaging for quicker, easier and more accurate diagnosis at the point-of-care. Strongly committed to R&D and design, Planmed Oy exports more than 98% of its production to over 70 countries worldwide. Planmed Oy, headquartered in Helsinki, Finland, was established in 1989. Planmed Oy is part of the Finland-based Planmeca Group that manufactures and markets state-of-the-art products for medical and dental fields.